$SNEX

Smith Philip Andrew sold $6.1M of SNEX

Smith Philip Andrew (Chief Executive Officer) sold 51,540 shares of StoneX Group Inc. (SNEX) at an average of $118.72 ($118.67–$118.75, $6.12M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith Philip Andrew
Published Jul 1, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

This provides a concrete datapoint on insider activity and execution timing, but it does not introduce new company fundamentals (no earnings, guidance, deal, or regulatory action).

02

Market read

Traders may monitor insider activity for sentiment, but the planned nature of the sale reduces the likelihood of a fundamental repricing.

03

What to watch

10b5-1 plans can be executed regardless of fundamentals; without changes to guidance, earnings, or strategy, the trading signal is usually muted.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 disclosure (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction: CEO Philip Andrew Smith sold shares via an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX CEO Philip Andrew Smith sold 51,540 shares in open-market transactions on 2026-06-30 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a pre-arranged 10b5-1 plan; it discloses sale size, price range, and post-transaction holdings without any new operating or guidance catalyst.

Market effects

Minimal; insider selling at a single broker-dealer/financial services firm rarely resets sector expectations.

None indicated.

None indicated.

Counterpoint

Because the CEO sold at ~$118.7, some traders may interpret it as a valuation/positioning signal despite the 10b5-1 structure.

Key entities

  • StoneX Group Inc.

    Subject of the Form 4 insider sale; ticker SNEX.

  • Philip Andrew Smith

    CEO and director who executed the open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.